Management of Adrenocortical Carcinoma

Sina Jasim, Mouhammed Amir Habra

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Purpose of Review: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy typically with poor prognosis. This review aims to summarize the current knowledge regarding the clinical management of ACC. Recent Findings: Surgery remains the cornerstone for localized ACC management. In more advanced cases, debulking surgery when feasible can help with hormonal control and may allow the initiation of systemic therapy. Over the last few years, our understanding of ACC molecular pathogenesis has expanded with no significant change in treatment options. Platinum-based chemotherapy is the gold standard in metastatic ACC despite suboptimal efficacy. Tyrosine kinase inhibitor use did not result in meaningful benefit in ACC patients. Multiple clinical trials are currently exploring the role of immunotherapy in ACC. Summary: Despite the remarkable improvement in our understanding of the molecular signature and pathways in ACC, this knowledge did not yield a major breakthrough in management of advanced ACC. Multi-institutional and international collaborations are needed to identify promising treatments and new therapeutic targets to improve the care of ACC patients.

Original languageEnglish
Article number20
JournalCurrent oncology reports
Issue number3
StatePublished - Mar 1 2019


  • Adrenocortical carcinoma
  • Genomic profiling
  • Immunotherapy
  • Mitotane
  • Targeted therapy


Dive into the research topics of 'Management of Adrenocortical Carcinoma'. Together they form a unique fingerprint.

Cite this